EUVIMEDEUVIMED entdecken
Crossref

Aprocitentan: A New Frontier in Hypertension Management

Rutuja.S.Dagale Rutuja.S.Dagale, Sneha.B.Sable Sneha.B.Sable, Miss Sonali bhangare Miss Sonali bhangare, Dr. Pallavi Phalke Dr. Pallavi Phalke

International Journal of Pharmaceutical Science Invention · 2024

DOI: 10.35629/6718-13060810 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Pharmaceutical Science Invention, 2024. Verfasst von Rutuja.S.Dagale Rutuja.S.Dagale und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aprocitentant is a novel antagonist of the neurokinin-1 (NK1) receptor, primarily developed for the treatment of chemotherapy-induced nausea and vomiting (CINV). This review provides a comprehensive analysis of its pharmacokinetics, clinical trial outcomes, and overall efficacy. Through a critical evaluation of existing studies, we assess its therapeutic potential, side effects, and overall significance in improving patient quality of life.

Zitieren

APA

Rutuja.S.Dagale, R., Sneha.B.Sable, S., bhangare, M. S. B. M. S., & Phalke, D. P. P. D. P. (2024). Aprocitentan: A New Frontier in Hypertension Management. International Journal of Pharmaceutical Science Invention. https://doi.org/10.35629/6718-13060810

Vancouver

Rutuja.S.Dagale R, Sneha.B.Sable S, bhangare MSBMS, Phalke DPPDP. Aprocitentan: A New Frontier in Hypertension Management. International Journal of Pharmaceutical Science Invention. 2024. doi:10.35629/6718-13060810

BibTeX
@article{RutujaSDagale2024,
  author = {Rutuja.S.Dagale, Rutuja.S.Dagale and Sneha.B.Sable, Sneha.B.Sable and bhangare, Miss Sonali bhangare Miss Sonali and Phalke, Dr. Pallavi Phalke Dr. Pallavi},
  title = {Aprocitentan: A New Frontier in Hypertension Management},
  journal = {International Journal of Pharmaceutical Science Invention},
  year = {2024},
  doi = {10.35629/6718-13060810}
}
Kostenlos starten →